Celltrion Healthcare, Stock Price -0.29% at This Time... Institutional Investors Net Buy 200,422 Shares in Last 5 Days

As of 1:32 PM on the 18th, Celltrion Healthcare is trading at 103,900 KRW, down 0.29% from the previous day. The trading volume is 1,457,129 shares, which is about 46.47% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.

On August 14, Kiwoom Securities researcher Heo Hyemin stated, "The COVID-19 treatment developed by Celltrion is expected to have data released by the end of this year, with the possibility of emergency approval depending on the results, and the company holds worldwide sales rights. There is anticipation for the launch of Humira biosimilar in Europe in Q1 2021, and based on Phase 4 data of Remsima SC in Europe, there are plans for direct sales of Remsima SC in the U.S. in 2022, indicating that the company is gradually transforming into a global pharmaceutical company," and set the target price for Celltrion Healthcare at 150,000 KRW.

Over the past five days, individual investors have net sold 41,285 shares of Celltrion Healthcare, while foreigners and institutions have net sold 162,791 shares and net bought 200,422 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.